Literature DB >> 11788719

Allosteric inhibitors of telomerase: oligonucleotide N3'-->P5' phosphoramidates.

Ronald Pruzan1, Krisztina Pongracz, Kimberly Gietzen, Gerald Wallweber, Sergei Gryaznov.   

Abstract

Telomerase is a ribonucleoprotein responsible for maintaining telomeres in nearly all eukaryotic cells. The enzyme is able to utilize a short segment of its RNA subunit as the template for the reverse transcription of d(TTAGGG) repeats onto the ends of human chromosomes. Transfection with telomerase was shown to confer immortality on several types of human cells. Moreover, telomerase activation appears to be one of the key events required for malignant transformation of normal cells. Inhibition of telomerase activity in transformed cells results in the cessation of cell proliferation in cultures and provides the rationale for the selection of telomerase as a target for anticancer therapy. Using oligonucleotide N3'-->P5' phosphoramidates (NPs) we have identified a region of the human telomerase RNA subunit (hTR) approximately 100 nt downstream from the template region whose structural integrity appears crucial for telomerase enzymatic activity. The oligonucleotides targeted to this segment of hTR are potent and specific inhibitors of telomerase activity in biochemical assays. Mutant telomerase, in which 3 nt of hTR were not complementary to a 15 nt NP, was found to be refractory to inhibition by that oligonucleotide. We also demonstrated that the binding of NP, oligonucleotides to this hTR allosteric site results in a marked decrease in the affinity of a telomerase substrate (single-stranded DNA primer) for the enzyme.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11788719      PMCID: PMC99832          DOI: 10.1093/nar/30.2.559

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  35 in total

1.  A telomerase component is defective in the human disease dyskeratosis congenita.

Authors:  J R Mitchell; E Wood; K Collins
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

2.  Secondary structure of vertebrate telomerase RNA.

Authors:  J L Chen; M A Blasco; C W Greider
Journal:  Cell       Date:  2000-03-03       Impact factor: 41.582

3.  Telomerase inhibitors--oligonucleotide phosphoramidates as potential therapeutic agents.

Authors:  S Gryaznov; K Pongracz; T Matray; R Schultz; R Pruzan; J Aimi; A Chin; C Harley; B Shea-Herbert; J Shay; Y Oshima; A Asai; Y Yamashita
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2001 Apr-Jul       Impact factor: 1.381

4.  SV40-INDUCED TRANFORMATION OF HUMAN DIPLOID CELLS: CRISIS AND RECOVERY.

Authors:  A J GIRARDI; F C JENSEN; H KOPROWSKI
Journal:  J Cell Comp Physiol       Date:  1965-02

5.  Analysis of telomerase catalytic subunit mutants in vivo and in vitro in Schizosaccharomycespombe.

Authors:  C H Haering; T M Nakamura; P Baumann; T R Cech
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 6.  Oligonucleotide N3'-->P5' phosphoramidates as potential therapeutic agents.

Authors:  S M Gryaznov
Journal:  Biochim Biophys Acta       Date:  1999-12-10

7.  Inhibition of telomerase limits the growth of human cancer cells.

Authors:  W C Hahn; S A Stewart; M W Brooks; S G York; E Eaton; A Kurachi; R L Beijersbergen; J H Knoll; M Meyerson; R A Weinberg
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

8.  Human H/ACA small nucleolar RNPs and telomerase share evolutionarily conserved proteins NHP2 and NOP10.

Authors:  V Pogacić; F Dragon; W Filipowicz
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

9.  2-5A antisense telomerase RNA therapy for intracranial malignant gliomas.

Authors:  S Mukai; Y Kondo; S Koga; T Komata; B P Barna; S Kondo
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

10.  In vitro assembly of human H/ACA small nucleolar RNPs reveals unique features of U17 and telomerase RNAs.

Authors:  F Dragon; V Pogacić; W Filipowicz
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

View more
  7 in total

1.  The solution structure of an essential stem-loop of human telomerase RNA.

Authors:  Thomas Leeper; Nicolas Leulliot; Gabriele Varani
Journal:  Nucleic Acids Res       Date:  2003-05-15       Impact factor: 16.971

2.  Targeting human telomerase for cancer therapeutics.

Authors:  Lionel Guittat; Patrizia Alberti; Dennis Gomez; Anne De Cian; Gaëlle Pennarun; Thibault Lemarteleur; Chafke Belmokhtar; Rajaa Paterski; Hamid Morjani; Chantal Trentesaux; Eliane Mandine; François Boussin; Patrick Mailliet; Laurent Lacroix; Jean-François Riou; Jean-Louis Mergny
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

3.  Mapping targetable sites on human telomerase RNA pseudoknot/template domain using 2'-OMe RNA-interacting polynucleotide (RIPtide) microarrays.

Authors:  Lourdes Gude; Shaunna S Berkovitch; Webster L Santos; Peter S Kutchukian; Adam R Pawloski; Robert Kuimelis; Glenn McGall; Gregory L Verdine
Journal:  J Biol Chem       Date:  2012-03-26       Impact factor: 5.157

4.  P-stereocontrolled synthesis of oligo(nucleoside N3'→O5' phosphoramidothioate)s - opportunities and limitations.

Authors:  Ewa Radzikowska; Renata Kaczmarek; Dariusz Korczyński; Agnieszka Krakowiak; Barbara Mikołajczyk; Janina Baraniak; Piotr Guga; Kraig A Wheeler; Tomasz Pawlak; Barbara Nawrot
Journal:  RSC Adv       Date:  2020-09-23       Impact factor: 4.036

Review 5.  Pancreatic cancer stem cells: fact or fiction?

Authors:  Vikash J Bhagwandin; Jerry W Shay
Journal:  Biochim Biophys Acta       Date:  2009-02-21

Review 6.  Telomerase inhibition in cancer therapeutics: molecular-based approaches.

Authors:  A P Cunningham; W K Love; R W Zhang; L G Andrews; T O Tollefsbol
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

7.  Determinants in mammalian telomerase RNA that mediate enzyme processivity and cross-species incompatibility.

Authors:  Jiunn-Liang Chen; Carol W Greider
Journal:  EMBO J       Date:  2003-01-15       Impact factor: 11.598

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.